We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-5.12%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$6.23B
AUM Growth
-$401M
Cap. Flow
+$712M
Cap. Flow %
11.42%
Top 10 Hldgs %
46.21%
Holding
101
New
19
Increased
9
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$193M
2
JBIO
Jade Biosciences
JBIO
+$189M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$104M
4
LENZ
LENZ Therapeutics
LENZ
+$67.1M
5
CNTB
Connect Biopharma Holdings
CNTB
+$66.7M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$92.3M
2
NVAX icon
Novavax
NVAX
+$81M
3
IGMS
IGM Biosciences
IGMS
+$75.4M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$52.4M
5
TGTX icon
TG Therapeutics
TGTX
+$50.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0.5%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
76
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$9.98M 0.16%
1,000,000
– –
TXMD icon
77
TherapeuticsMD
TXMD
$25M
$9.3M 0.15%
156,250
– –
CGEM icon
78
Cullinan Oncology
CGEM
$1.32B
$9.01M 0.14%
350,000
– –
COGT icon
79
Cogent Biosciences
COGT
$5.68B
$8.32M 0.13%
1,025,641
– –
BMEA icon
80
Biomea Fusion
BMEA
$130M
$7.8M 0.13%
+500,000
New +$8.83M
CVRX icon
81
CVRx
CVRX
$79.9M
$7.7M 0.12%
+275,000
New +$7.7M
FVAM
82
DELISTED
5:01 Acquisition Corp
FVAM
$7.48M 0.12%
750,000
– –
MLTX icon
83
MoonLake Immunotherapeutics
MLTX
$1.04B
$7.25M 0.12%
700,000
– –
OBIO icon
84
Orchestra BioMed
OBIO
$363M
$6.38M 0.1%
625,000
– –
VRDN icon
85
Viridian Therapeutics
VRDN
$2.47B
$5.71M 0.09%
312,328
– –
SYRS
86
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.91M 0.08%
90,000
– –
WHWK
87
Whitehawk Therapeutics
WHWK
$233M
$4.55M 0.07%
+179,554
New +$4.1M
CEREW
88
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$3.36M 0.05%
233,333
– –
NTLA icon
89
Intellia Therapeutics
NTLA
$1.59B
$2.43M 0.04%
+15,000
New +$1.17M
ELVN icon
90
Enliven Therapeutics
ELVN
$3.91B
$1.97M 0.03%
62,201
– –
MCRB icon
91
Seres Therapeutics
MCRB
$46.2M
$1.9M 0.03%
255,277
+70,567
+38% +$29.8M
OKUR
92
OnKure Therapeutics
OKUR
$119M
$580K 0.01%
+6,222
New +$694K
ADVM
93
DELISTED
Adverum Biotechnologies
ADVM
– –
-936,583
Closed -$92.3M
IGMS
94
DELISTED
IGM Biosciences
IGMS
– –
-982,723
Closed -$75.4M
PRQR icon
95
ProQR Therapeutics
PRQR
$260M
– –
-2,117,669
Closed -$14M
RLAY icon
96
Relay Therapeutics
RLAY
$4.16B
– –
-1,000,000
Closed -$34.6M
RPTX
97
DELISTED
Repare Therapeutics
RPTX
– –
-409,000
Closed -$12.6M
SNDX icon
98
Syndax Pharmaceuticals
SNDX
$1.62B
– –
-1,023,067
Closed -$22.9M
STRO icon
99
Sutro Biopharma
STRO
$275M
– –
-211,821
Closed -$48.2M
XFOR icon
100
X4 Pharmaceuticals
XFOR
$359M
– –
-17,899
Closed -$4.62M
1 2 3
4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, RA Capital Management held 101 positions worth $6.23B, down 6.1% from $6.63B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $712M of net new capital in Q2 2021, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was Janux Therapeutics: 8,670,644 shares worth $216M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $81M trimmed.

  • RA Capital Management's largest Q2 2021 buy was Janux Therapeutics: 8,670,644 shares worth $216M.
  • RA Capital Management added most to Connect Biopharma Holdings in Q2 2021, an estimated $66.7M increase.
  • RA Capital Management's biggest Q2 2021 reduction was Novavax, cutting an estimated $81M.
  • RA Capital Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $92.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $6.23B portfolio in Q2 2021.
  • RA Capital Management opened 19 new positions and closed 9 in Q2 2021.
  • RA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $6.23B.

Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.